Actively Recruiting
Long-Term Open-Label Extension Study of Avalyn Inhaled Antifibrotic Agent AP01 Evaluating Safety and Tolerability in Progressive Pulmonary Fibrosis and Idiopathic Pulmonary Fibrosis
Led by Avalyn Pharma Inc. · Updated on 2026-10-02
340
Participants Needed
85
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the long-term safety and tolerability of inhaled antifibrotic medications, specifically AP01, in participants who have previously completed Avalyn Pharma sponsored studies involving this treatment. The study focuses on individuals with progressive pulmonary fibrosis or idiopathic pulmonary fibrosis IPF, excluding IPF subjects from the US and Canada. The goal is to continue assessing the effects of AP01 over an extended period. Participants will receive 100 mg of inhaled pirfenidone solution AP01 twice daily using the eFlow Nebulizer System. The study includes a ScreeningBaseline Visit, an open-label Treatment Period where all participants receive AP01, and a Follow-upEnd of Study phone call approximately two weeks after the last dose. The dosing during the treatment period will be monitored with a paper diary and by collecting any unused medication. Throughout the study, participants will be assessed for long-term safety and tolerability outcomes, including changes in lung function measured by forced vital capacity FVC, disease stabilization, and quality of life. The trial is expected to last an average of six years, with evaluations continuing until the studys end. Participants will have regular monitoring and follow-up to track their progress and adherence to the treatment.
CONDITIONS
Brief Title
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Research Team
D
Dr. Felix Woodhead, MB BChir,PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here